Aim: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal cancer patients. Standard administration schedule is once a week; however, the bioequivalence of an every-other-week (EOW) schedule was demonstrated. Methods: We compared a base case scenario of 100% weekly administration to an EOW at 50 or 100%. Medical examinations, patient management and loss of productivity were considered. Results: Base case was estimated at €100.6 million versus €92.8 million and €84.9 million of EOW 50 and 100%, which showed a cost reduction of 8 and 16%, respectively. Indirect costs accounted for 65% in both scenarios. Conclusion: The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.

Mennini, F.s., Marcellusi, A., Fabiano, G., Rimassa, L., Santoro, A., & Personeni, N. (2019). Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. FUTURE ONCOLOGY, 15(18), 2107-2112 [10.2217/fon-2018-0904].

Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer

Mennini F. S.
Methodology
;
2019

Abstract

Aim: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal cancer patients. Standard administration schedule is once a week; however, the bioequivalence of an every-other-week (EOW) schedule was demonstrated. Methods: We compared a base case scenario of 100% weekly administration to an EOW at 50 or 100%. Medical examinations, patient management and loss of productivity were considered. Results: Base case was estimated at €100.6 million versus €92.8 million and €84.9 million of EOW 50 and 100%, which showed a cost reduction of 8 and 16%, respectively. Indirect costs accounted for 65% in both scenarios. Conclusion: The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore SECS-P/03 - Scienza delle Finanze
English
bi-monthly administration; budget impact; cetuximab
Mennini, F.s., Marcellusi, A., Fabiano, G., Rimassa, L., Santoro, A., & Personeni, N. (2019). Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. FUTURE ONCOLOGY, 15(18), 2107-2112 [10.2217/fon-2018-0904].
Mennini, Fs; Marcellusi, A; Fabiano, G; Rimassa, L; Santoro, A; Personeni, N
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Future Oncology_2019.pdf

accesso aperto

Licenza: Non specificato
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/219257
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact